We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher Corporation’s (DHR - Free Report) fourth-quarter 2023 adjusted earnings (excluding 59 cents from non-recurring items) of $2.09 per share surpassed the Zacks Consensus Estimate of $1.90. The bottom line declined 17.7% year over year.
Danaher’s net sales of $6,405 million outperformed the consensus estimate of $5,990 million. However, the metric declined 10.2% year over year due to a decrease in sales of COVID-related products and weakness in the Biotechnology and Diagnostics segments.
Organic sales in the quarter decreased 11.5%. Foreign-currency translations and acquisitions had a positive impact of 1% and 0.5%, respectively, on quarterly sales. Base business core sales (adjusted) declined 4.5% in the quarter.
For 2023, Danaher reported net sales of $23.9 billion, declining 10.3% year over year. For the year, the company’s adjusted earnings came in at $7.58 per share compared with $9.71 in 2022.
Danaher Corporation Price, Consensus and EPS Surprise
On Sep 30, 2023, Danaher completed the separation of its Environmental & Applied Solutions segment. It currently operates under the operating segments discussed below.
Revenues from the Life Sciences segment totaled $1.93 billion, down 1% year over year. Core sales dipped 4% year over year. Acquisitions/divestitures led to a 2.5% increase in sales. Operating profit was $235 million for the quarter, down 40% year over year. We expected the Life Sciences segment’s revenues to be $1.84 billion.
Revenues from the Diagnostics segment totaled $2.72 billion, down 8.5% year over year. Our estimate for revenues in the quarter was $2.37 billion. The downside was due to an 8.5% decline in core sales. Foreign currency or acquisitions did not have any material impact on sales. Operating profit was $766 million for the quarter, down 22.5% on a year-over-year basis.
Revenues from the Biotechnology segment totaled $1.76 billion, down 21% year over year. Our estimate for the quarter was $1.68 billion. Core sales dropped 22.5% for the segment. Operating profit was $416 million for the quarter, down 40% year over year.
Margin Profile
In the fourth quarter, Danaher’s cost of sales decreased 9.7% year over year to $2.63 billion. Gross profit of $3.78 billion fell 10.6% year over year. Gross margin in the quarter was 59% compared with 59.2% in the year-ago quarter.
Selling, general and administrative expenses of $2.04 billion, an increase of 11.3% on a year-over-year basis. Research and development expenses were $407 million, up nearly 1.8% year over year.
Danaher’s operating profit in the reported quarter dropped 33% year over year to $1.34 billion. Operating margin decreased to 20.9% from 28% in the year-ago quarter.
Balance Sheet and Cash Flow
Exiting the fourth quarter, DHR had cash and equivalents of $5.86 billion compared with about $6 billion at 2022-end. Long-term debt was $16.7 billion at the end of the reported quarter compared with $19.1 billion at the end of December 2022.
Danaher generated net cash of $7.16 billion from operating activities in 2023 compared with $8.52 billion in the previous year. Capital expenditures totaled $1.38 billion in the same period, up 23.7% year over year. Adjusted free cash flow was $5.1 billion in 2023 compared with $6.5 billion in the previous year.
In 2023, DHR paid out dividends of $821 million, up around 0.4% on a year-over-year basis.
Outlook
For the first quarter of 2024, Danaher expects adjusted core revenues from continuing operations to decline in high-single digits on a year-over-year basis.
The same is anticipated to decrease in low-single digits on a year-over-year basis in 2024.
Zacks Rank & Stocks to Consider
Danaher presently carries a Zacks Rank #3 (Hold).
Here are some better-ranked stocks from the same space:
ITT delivered a trailing four-quarter average earnings surprise of 8%. In the past 60 days, the Zacks Consensus Estimate for ITT’s 2023 earnings has increased by a penny. The stock has risen 32.8% in the past three months.
Flowserve Corporation (FLS - Free Report) presently carries a Zacks Rank of 2. FLS delivered a trailing four-quarter average earnings surprise of 27.3%.
In the past 60 days, the Zacks Consensus Estimate for Flowserve’s 2023 earnings has remained steady. The stock has risen 12.4% in the past three months.
Crane Company (CR - Free Report) currently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 25.1%.
In the past 60 days, the Zacks Consensus Estimate for Crane’s 2024 earnings has increased 0.6%. The stock has risen 20.9% in the past three months.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Danaher (DHR) Q4 Earnings Beat, Biotechnology Sales Dip Y/Y
Danaher Corporation’s (DHR - Free Report) fourth-quarter 2023 adjusted earnings (excluding 59 cents from non-recurring items) of $2.09 per share surpassed the Zacks Consensus Estimate of $1.90. The bottom line declined 17.7% year over year.
Danaher’s net sales of $6,405 million outperformed the consensus estimate of $5,990 million. However, the metric declined 10.2% year over year due to a decrease in sales of COVID-related products and weakness in the Biotechnology and Diagnostics segments.
Organic sales in the quarter decreased 11.5%. Foreign-currency translations and acquisitions had a positive impact of 1% and 0.5%, respectively, on quarterly sales. Base business core sales (adjusted) declined 4.5% in the quarter.
For 2023, Danaher reported net sales of $23.9 billion, declining 10.3% year over year. For the year, the company’s adjusted earnings came in at $7.58 per share compared with $9.71 in 2022.
Danaher Corporation Price, Consensus and EPS Surprise
Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation Quote
Segmental Discussion in Q4
On Sep 30, 2023, Danaher completed the separation of its Environmental & Applied Solutions segment. It currently operates under the operating segments discussed below.
Revenues from the Life Sciences segment totaled $1.93 billion, down 1% year over year. Core sales dipped 4% year over year. Acquisitions/divestitures led to a 2.5% increase in sales. Operating profit was $235 million for the quarter, down 40% year over year. We expected the Life Sciences segment’s revenues to be $1.84 billion.
Revenues from the Diagnostics segment totaled $2.72 billion, down 8.5% year over year. Our estimate for revenues in the quarter was $2.37 billion. The downside was due to an 8.5% decline in core sales. Foreign currency or acquisitions did not have any material impact on sales. Operating profit was $766 million for the quarter, down 22.5% on a year-over-year basis.
Revenues from the Biotechnology segment totaled $1.76 billion, down 21% year over year. Our estimate for the quarter was $1.68 billion. Core sales dropped 22.5% for the segment. Operating profit was $416 million for the quarter, down 40% year over year.
Margin Profile
In the fourth quarter, Danaher’s cost of sales decreased 9.7% year over year to $2.63 billion. Gross profit of $3.78 billion fell 10.6% year over year. Gross margin in the quarter was 59% compared with 59.2% in the year-ago quarter.
Selling, general and administrative expenses of $2.04 billion, an increase of 11.3% on a year-over-year basis. Research and development expenses were $407 million, up nearly 1.8% year over year.
Danaher’s operating profit in the reported quarter dropped 33% year over year to $1.34 billion. Operating margin decreased to 20.9% from 28% in the year-ago quarter.
Balance Sheet and Cash Flow
Exiting the fourth quarter, DHR had cash and equivalents of $5.86 billion compared with about $6 billion at 2022-end. Long-term debt was $16.7 billion at the end of the reported quarter compared with $19.1 billion at the end of December 2022.
Danaher generated net cash of $7.16 billion from operating activities in 2023 compared with $8.52 billion in the previous year. Capital expenditures totaled $1.38 billion in the same period, up 23.7% year over year. Adjusted free cash flow was $5.1 billion in 2023 compared with $6.5 billion in the previous year.
In 2023, DHR paid out dividends of $821 million, up around 0.4% on a year-over-year basis.
Outlook
For the first quarter of 2024, Danaher expects adjusted core revenues from continuing operations to decline in high-single digits on a year-over-year basis.
The same is anticipated to decrease in low-single digits on a year-over-year basis in 2024.
Zacks Rank & Stocks to Consider
Danaher presently carries a Zacks Rank #3 (Hold).
Here are some better-ranked stocks from the same space:
ITT Inc. (ITT - Free Report) presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
ITT delivered a trailing four-quarter average earnings surprise of 8%. In the past 60 days, the Zacks Consensus Estimate for ITT’s 2023 earnings has increased by a penny. The stock has risen 32.8% in the past three months.
Flowserve Corporation (FLS - Free Report) presently carries a Zacks Rank of 2. FLS delivered a trailing four-quarter average earnings surprise of 27.3%.
In the past 60 days, the Zacks Consensus Estimate for Flowserve’s 2023 earnings has remained steady. The stock has risen 12.4% in the past three months.
Crane Company (CR - Free Report) currently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 25.1%.
In the past 60 days, the Zacks Consensus Estimate for Crane’s 2024 earnings has increased 0.6%. The stock has risen 20.9% in the past three months.